{
    "clinical_study": {
        "@rank": "144764", 
        "arm_group": [
            {
                "arm_group_label": "Dose 1 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 2 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 3 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 4 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 5 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 6 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 7 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 8 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 9 JTT-251 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, and PK (Pharmacokinetics)\n      of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to\n      evaluate the effect of food on the PK of JTT-251 in healthy subjects."
        }, 
        "brief_title": "Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy Subject Cohorts:\n\n          -  Healthy male or female subjects\n\n          -  Body Mass Index (BMI) between 19.0 and 31.0 kg/m2 (inclusive)\n\n        Type 2 Diabetic Subject Cohorts:\n\n          -  Male or female Type 2 diabetic subjects diagnosed for at least 3 months\n\n          -  BMI between 25 and 40 kg/m2 (inclusive)\n\n          -  Have a glycosylated hemoglobin (HbA1c) of >6.5% to \u226410.9% (inclusive) if treatment\n             na\u00efve with respect to hypoglycemic agents OR >6.5% to \u226410.0% (inclusive) if treated\n             with metformin\n\n        Exclusion Criteria:\n\n        Healthy Subject Cohorts:\n\n          -  Known clinically relevant history or presence of significant respiratory,\n             gastrointestinal, renal, hepatic, hematological, lymphatic, neurological,\n             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,\n             metabolic, and dermatological or connective tissue disease\n\n          -  Subjects with a systolic blood pressure >150 mmHg and/or diastolic blood pressure >90\n             mmHg\n\n        Type 2 Diabetic Subject Cohorts:\n\n          -  Subjects with a known medical history or presence of type 1 diabetes mellitus\n\n          -  Subjects with known medical history of acute metabolic diabetic complications\n\n          -  Subjects with uncontrolled hypertension (systolic blood pressure >160 mmHg and/or\n             diastolic blood pressure >95 mmHg with documented ongoing treatment)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106585", 
            "org_study_id": "AT251-U-13-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Dose 1 JTT-251 or Placebo", 
                "Dose 2 JTT-251 or Placebo", 
                "Dose 3 JTT-251 or Placebo", 
                "Dose 4 JTT-251 or Placebo", 
                "Dose 5 JTT-251 or Placebo", 
                "Dose 6 JTT-251 or Placebo", 
                "Dose 7 JTT-251 or Placebo", 
                "Dose 8 JTT-251 or Placebo", 
                "Dose 9 JTT-251 or Placebo"
            ], 
            "description": "Subjects will receive JTT-251 or Placebo", 
            "intervention_name": "JTT-251 or Placebo", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Safety", 
            "Tolerability", 
            "Pharmacokinetics", 
            "Food-effect", 
            "Diabetes"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "9", 
        "official_title": "Phase 1, Randomized, Single-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of JTT-251 Single Oral Doses in Healthy Subjects (Part Ia) and in Type 2 Diabetic Subjects (Part Ib) and Randomized, Open-label, Crossover Study Evaluating Effect of Food on PK in Healthy Subjects (Part II)", 
        "overall_contact": {
            "email": "yamamotoh@akrospharma.com", 
            "last_name": "Hideyuki Yamamoto", 
            "phone": "609-919-6111"
        }, 
        "overall_official": {
            "affiliation": "Akros Pharma Inc.", 
            "last_name": "Hideyuki Yamamoto", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Vital signs and 12 lead ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Cmax (maximum concentration)", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "t1/2 (elimination half-life)", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "AUC (area under the concentration-time curve)", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval)", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106585"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Akros Pharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Akros Pharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}